OIG Advisory Opinion: 22-05
Favorable
Paying FMV site fees and patient cost-sharing in a CMS-approved device trial
Recorded opinion date:
Source documents
Preparing document preview…
Paying FMV site fees and patient cost-sharing in a CMS-approved device trial
The commentary below transcribes Cabra's existing summary PDF. It preserves the original analysis, including its checklist and wording. The original PDF remains available below. Advisory opinions concern their particular facts and requestors; this commentary is not legal advice.
What OIG Said
OIG said this setup can be okay if site payments are FMV, patient subsidies aren’t marketed, and nothing is tied to referrals or future use.
✓OIG reviewed a device company running a CMS-approved clinical trial. The sponsor paid sites and investigators, and subsidized Medicare patient cost-sharing (~$1,300) to encourage enrollment and retention.
✓OIG said these payments do count as remuneration, which could trigger Anti-Kickback or Beneficiary Inducements scrutiny.
✓But they accepted the structure because site payments were certified as fair market value, and the company wasn’t using subsidies to steer referrals or lock in future use.
✓OIG also noted the therapy was a one-time treatment, not expected to drive downstream utilization, which reduced seeding concerns.
OIG WATCH | info@cabraconsulting.com
Diligence Checklist
What you need to be ready to show in diligence
✓Have written FMV certification for all investigator and site payments, no volume linkage or side deals.
✓Prove that patient cost-sharing subsidies weren’t advertised or selectively offered and were clearly disclosed only in the IRB-approved consent.
✓Show CMS approval of the trial and Category B IDE status under Medicare rules.
✓Document that the product has no anticipated downstream reimbursement tail or re-use trigger.
✓Confirm all sites were selected using objective, non-referral-based criteria (e.g. IRB timeline, staffing, enrollment capacity).
If your cost-sharing subsidies or site payments look like selective inducement, you’ll face serious defensibility questions if scrutinized.
OIG WATCH | info@cabraconsulting.com
Structure not diligence-ready?
Cabra Consulting helps healthcare organizations make sure compensation and transaction structures are independently valued, clearly scoped, and defensible in diligence.
OIG WATCH | info@cabraconsulting.com
Original PDF cover text
FAVORABLE
OIG WATCH 22-05
Paying FMV site fees and patient cost-sharing in a CMS-approved device trial
Cabra commentary publication date is not recorded in the existing source. No publication or revision date has been inferred from this HTML conversion.